These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28571121)

  • 1. Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop.
    Zhang X; Duan J; Kesisoglou F; Novakovic J; Amidon GL; Jamei M; Lukacova V; Eissing T; Tsakalozou E; Zhao L; Lionberger R
    CPT Pharmacometrics Syst Pharmacol; 2017 Aug; 6(8):492-495. PubMed ID: 28571121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
    Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
    AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling and simulation of biopharmaceutical performance.
    Zhang X; Lionberger RA
    Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products.
    Wu F; Mousa Y; Jereb R; Batchelor H; Chakraborty S; Heimbach T; Stier E; Kesisoglou F; Kollipara S; Zhang L; Zhao L
    AAPS J; 2024 Jan; 26(1):19. PubMed ID: 38267737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole.
    Cristofoletti R; Patel N; Dressman JB
    J Pharm Sci; 2017 Feb; 106(2):560-569. PubMed ID: 27865610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products.
    Mitra A; Petek B; Bajc A; Velagapudi R; Legen I
    Eur J Pharm Biopharm; 2019 Jan; 134():117-125. PubMed ID: 30472143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing the Impact of Physiologically Based Oral Absorption Modeling and Simulation.
    Chung JI; Kelly RC; Wahlstrom J; Wu B; Wu T; Alvarez-Nunez F
    J Pharm Sci; 2017 Mar; 106(3):734-737. PubMed ID: 27915208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation.
    Jiang W; Kim S; Zhang X; Lionberger RA; Davit BM; Conner DP; Yu LX
    Int J Pharm; 2011 Oct; 418(2):151-60. PubMed ID: 21803144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance.
    Tsume Y; Patel S; Fotaki N; Bergstrӧm C; Amidon GL; Brasseur JG; Mudie DM; Sun D; Bermejo M; Gao P; Zhu W; Sperry DC; Vertzoni M; Parrott N; Lionberger R; Kambayashi A; Hermans A; Lu X; Amidon GE
    AAPS J; 2018 Sep; 20(6):100. PubMed ID: 30191341
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Physiologically Based Oral Absorption Modelling in Formulation Development Under a Quality by Design Paradigm.
    Kesisoglou F
    J Pharm Sci; 2017 Apr; 106(4):944-949. PubMed ID: 27964940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH.
    Zhu H; Chen X; Ahmed M; Wang Y; Liu Q; Uppoor RS; Kuemmel C; Mehta M
    Clin Transl Sci; 2019 Nov; 12(6):564-572. PubMed ID: 31169344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.
    Vaidhyanathan S; Wang X; Crison J; Varia S; Gao JZH; Saxena A; Good D
    J Pharm Sci; 2019 Jan; 108(1):741-749. PubMed ID: 30439460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products.
    Basu S; Yang H; Fang L; Gonzalez-Sales M; Zhao L; Trame MN; Lesko L; Schmidt S
    J Clin Pharmacol; 2019 Sep; 59(9):1252-1263. PubMed ID: 31087553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.